NASDAQ •
Healthcare •
Biotechnology •
Quote as of 09/11/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization725.42 mln
Float103 mln
Earnings Date11/05/2026
Piotroski F-Score
3
/ 9
Below average
1-Year Forecast
16.60
Transformational upside
Relative Strength
17
/ 100
Significantly lagging
Debt / Equity
0.05
Debt-free
ROE
-73.54
Deeply negative
ROA
-62.41
Deeply negative
Business Description
Aura Biosciences is a Boston-based clinical-stage company focused on developing targeted treatments for solid tumors. It uses a proprietary technology that attaches drugs or genetic material to virus-like particles, allowing them to seek out and attack cancer cells with greater precision. Its lead drug candidate, bel-sar, is being tested in advanced trials for eye melanoma and other eye cancers, as well as in earlier trials for bladder cancer.